Atonco, an innovative company specializing in the development of next-generation radiopharmaceuticals based on astatine-211, today announces the promotion of Alexandra Paillard to the position of Chief Operating Officer (COO), effective October 1, 2025.
In addition to this appointment, Alexandra Paillard will also take on the role of Deputy Chief Executive Officer, overseeing all operations related to the technical and clinical development of radiopharmaceuticals under Atonco’s license.
A Doctor of Pharmacy and holder of a PhD in pharmaceutical technology, Alexandra Paillard brings extensive experience in managing complex projects in biotechnology and pharmaceutical development. Her mission will be to strengthen and accelerate Atonco’s operational strategy around its core focus: astatine-211-based radiopharmaceuticals, notably ATO-101™, developed within a next-generation alpha-immunotherapy approach.
This appointment marks an important milestone in Atonco’s organizational development and confirms the company’s ambition to become a global reference player in targeted alpha radiotherapy.
“Alexandra Paillard’s promotion reflects our confidence in her ability to lead our operations into a new phase of growth and industrial scale-up. Her leadership will be decisive in realizing the unique therapeutic potential of our astatine-211-based radiopharmaceuticals,” said Sylvain Fanier, Chairman of Atonco.
“It is an honor to take on the leadership of Atonco’s operations at such a strategic moment in its development. Astatine-211 represents a unique opportunity to transform the treatment of many cancer patients, and I am fully committed to bringing, together with our teams and partners, our radiopharmaceutical portfolio — notably ATO-101™ — to the next clinical and industrial milestones,” said Alexandra Paillard.
About Atonco
Atonco is an innovative biopharmaceutical company dedicated to the development of next-generation radiopharmaceuticals based on astatine-211, a promising alpha emitter for targeted cancer therapies. Its lead program, ATO-101™, is developed under an exclusive license of girentuximab from Telix Pharmaceuticals, as part of a high-precision therapeutic approach against cancers resistant to conventional treatments.